Clinically relevant pharmacogenetic markers in Tatars and Balkars

Мирзаев, К. Б.; Burashnikova, I. S.; Shikaleva, AA; Качанова, А. А.; Abdullaev, Sh. P.; Акмалова, К. А.; Sozaeva, Zhannet A; Grishina, Elena A.; Sozaeva, Maryam Sultan-Hamitovna; Rytkin, Eric; Сычев, Д. А.

doi:10.1007/s11033-020-05416-4

Cited by 4 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Сопоставление наших данных с результатами других исследований в различных регионах России позволило сделать вывод, что в нашей стране 80-85% пациентов принадлежат к быстрым и нормальным метаболизаторам CYP2C19 (табл. 3) [10][11][12][13].…”

Section: Discussionunclassified

“…В метаанализе Y. Morino Казань, 2020 (русские) [13] 580 Ультрабыстрые метаболизаторы -26,8%, быстрые и нормальные -61,6%, промежуточные -11,3%, медленные метаболизаторы -0,3% Казань, 2020 (татары) [13] 282 Ультрабыстрые метаболизаторы -27,3%, быстрые и нормальные -56,1%, промежуточные -15,9%, медленные метаболизаторы -0,7%…”

Section: Discussionunclassified

See 1 more Smart Citation

The influence of CYP2C19 polymorphism on the effectiveness of the treatment of acid-dependent diseases

et al. 2022

View full text Add to dashboard Cite

Introduction. In modern systematic reviews, there is a point of view that CYP2C19 polymorphism affects the results of treatment of peptic ulcer, erosive esophagitis and eradication of Helicobacter pylori.Оbjective. To evaluate the effect of CYP2C19 polymorphism on the effectiveness of treatment with rabeprazole at a dose of 20 mg once a day in patients with GERD during 2 and 4 weeks of treatment.Materials and methods. In total, the study included 75 patients with GERD (36 men and 39 women, mean age 41.7 ± 1.5 years). A clinical examination with the completion of standard questionnaires took place during three visits: before the start of treatment, after 2 and after 4 weeks of therapy. Esophagogastroduodenoscopy was performed in all patients before treatment and in patients with esophagitis after 4 weeks of therapy. All patients received rabeprazole at a dose of 20 mg once a day. Genotyping of single nucleotide polymorphisms of CYP2C19 metabolizer genes was carried out by real-time polymerase chain reaction. Ultrarapid, rapid, normal, intermediate and poor CYP2C19 metabolizers have been isolated.Results. Of the 75 patients examined, 8.0% of patients were ultrarapid metabolizers, 30.7% of people were rapid, 49.3% of individuals were normal, 10.7% of persons were intermediate, and 1.3% of patients were poor CYP2C19 metabolizers. Response after 4 weeks of treatment with rabeprazole 20 mg once daily was 94.4% for NERD and 90.5% for erosive esophagitis. In ultrarapid and rapid metabolizers of CYP2C19, a complete response to rabeprazole therapy was registered in 81.3% of NERD patients and in 84.6% of patients with erosive esophagitis.Conclusion. Based on the results of the study, we obtained high efficacy of Razo® at a dose of 20 mg 1 time per day for the treatment of GERD in a group of patients with a predominance of rapid and normal metabolizers of CYP2C19.

show abstract

Section: Discussionunclassified

The influence of CYP2C19 polymorphism on the effectiveness of the treatment of acid-dependent diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Внедрение биомаркеров (на примере фармакогенетических) требует понимания распространённости клинически значимых для персонализированной фармакотерапии полиморфизмов генов в различных этнических группах России. В Академии активно изучаются особенности распределения генотипов по полиморфным маркерам изученных генов в различных этнических группах (мультиэтнический анализ проживающих в Россииэтнические группы Северного Кавказа, Поволжья, Сибири, Крыма и Дальнего Востока), как основа генетически обусловленной этнической чувствительности к лекарственным средствам и понимания приоритетности внедрения фармакогенетического тестирования [38][39][40][41][42][43].…”

Section: актуальные обзорыunclassified

Problems of integrating medical science, image and practical health care: focus on personalized medicine

Сычёв

2020

Fgen_Fgenom

View full text Add to dashboard Cite

On the example of technologies of personalization of pharmacotherapy based on biomarkers of the processes of absorption, distribution, metabolism and excretion of drugs (ADME-processes), the methodology of the results of scientific research into the educational process within the system of continuous medical education of doctors into the real clinical practice is presented. This methodology has been developed and implemented in the Russian Medical Academy of Continuing Professional Education.

show abstract

“…Показано, что у носителей вариантов CYP2C9*2 (rs1799853) и CYP2C9*3 (rs1057910) замедляется метаболизм НПВП, что ведет к увеличению плазменной концентрации препарата и повышению риска желудочно-кишечных кровотечений (ЖКК) [2,6]. Распространенность CYP2C9*2 и CYP2C9*3 в некоторых российских этнических группах была изучена нами ранее [7,8], но распределение вариантов гена CYP2C8 не охарактеризовано.…”

unclassified

“…Дополнительно был проанализирован характер совместного носительства вариантов генов CYP2C8 и CYP2C9 для кавказских этнических групп. Данные о носительстве аллельных вариантов CYP2C9*2 (c.430C>T, rs1799853) и CYP2C9*3 (c.1075A>C, rs1057910) в рассматриваемых этносах были взяты из ранее опубликованных нами работ [7,8]. Результаты приведены в табл.…”

unclassified

Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2

Denisenko

Abdullaev

Ryzhikova

et al. 2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) and PTGS2 (rs20417) among residents of the North Caucasus.Patients and methods. The study involved 676 volunteers from Russian, Balkar, Kabardian and Ossetian ethnic groups. Carriage of polymorphic markers CYP2C8, PTGS1 and PTGS2 was determined using real-time polymerase chain reaction.Results and discussion. There were no significant differences between the groups in the rs10509681 and rs11572080 variants of the CYP2C8 gene. In all groups, the carriage of a combination of CYP2C8 and CYP2C9 alleles, encoding the phenotype of normal metabolizers, prevailed with a frequency of about 75% or more. The rs10306135 variant of the PTGS1 gene was found in 5.9% of Russians, 1.1% of Balkars, 5.3% of Kabardians, and 10.6% of Ossetians; variant rs12353214 – in 19.1; 9.4; 10.8 and 9.2%, rs20417 polymorphism of the PTGS2 gene in 0.4; 5; 2.8 and 3.1% respectively.Conclusion. The data obtained can be used to develop a more rational approach to the prescription of NSAIDs, taking into account the genetic characteristics of the local population in ethnic regions.

show abstract

Clinically relevant pharmacogenetic markers in Tatars and Balkars

Cited by 4 publications

References 61 publications

The influence of CYP2C19 polymorphism on the effectiveness of the treatment of acid-dependent diseases

The influence of CYP2C19 polymorphism on the effectiveness of the treatment of acid-dependent diseases

Problems of integrating medical science, image and practical health care: focus on personalized medicine

Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2

Contact Info

Product

Resources

About